Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease.
Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.
Current Team (6)Update
Funding Rounds (7) - $116.3MUpdate
Board Members and Advisors (6)Update
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in...
Celgene discovers, develops and commercializes innovative therapies to treat cancer and...
Skyline Ventures, formed in 1997, is a nationally-known venture capital firm that specializes in...
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in...
Amgen engages in the development of human therapeutic products in supportive of cancer care,...
Venture capital Firm
International Biotechnology Trust (IBT) is an investment trust company listed on the London Stock...
310 Utah Ave
South San Francisco, CA 94080